Bicycle Therapeutics (BCYC) Cash & Equivalents (2018 - 2026)

Bicycle Therapeutics (BCYC) has 9 years of Cash & Equivalents data on file, last reported at $510.1 million in Q2 2026.

• Quarterly Cash & Equivalents fell 29.3% year-over-year to $510.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $510.1 million (down 29.3% YoY) and the FY2025 annual result came in at $628.1 million, down 28.58% from the prior year.
• Cash & Equivalents declined to $510.1 million in Q2 2026, from $559.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $961.4 million in Q2 2024 to a low of $293.8 million in Q1 2023.
• A 5-year average of $570.2 million and a median of $543.0 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents soared 182.39% — and 2026, when it dropped 29.44%.
• Tracing BCYC's Cash & Equivalents over 5 years: stood at $339.2 million in 2022, then soared by 55.22% to $526.4 million in 2023, then surged by 67.07% to $879.5 million in 2024, then retreated by 28.58% to $628.1 million in 2025, then slipped by 18.79% to $510.1 million in 2026.
• The last three Cash & Equivalents figures came in at $510.1 million (Q2 2026), $559.5 million (Q1 2026), and $628.1 million (Q4 2025), per Business Quant data.